Anthrax -- Worldwide/Unknown
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today [30 Jun 2020] announced dosing of the 1st patient in the Company's Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of USD 133.7 million if all options in the contract (HHSO100201600008C) are
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7526146&promed&0
No comments:
Post a Comment